Bristol’s Growth Plan Faces First Test In 2022

New Drugs Hit $1bn Mark In 2021, But First Revlimid Generics Launch This Year

 
• By Mandy Jackson

Zeposia, Reblozyl, Breyanzi and Abecma turned BMS’s new product portfolio into a blockbuster revenue stream last year to help fill the $3.5bn gap created by Revlimid and Abraxane generics.

Set of Three Increasing Size Red and White Cartoon Spaceships on Dark Background
BMS will launch three new products, pending approvals, in the US in 2022 • Source: Alamy

More from Earnings

More from Business